顺铂为基础的联合化疗对非小细胞肺癌患者血糖影响的临床观察  

Clinical research on blood glucose following cisplatin-based cheomtherapy in non-small cell lung cancer patients

作　　者：李建鹏[1] 朱志图[1] 巩克亭 邢永达[1] 郁云龙[1] 哈敏文[1] 

机构地区：[1]辽宁医学院附属第一医院肿瘤科,辽宁锦州121001 [2]新泰市计划生育服务站,山东泰安271200

出　　处：《中华肿瘤防治杂志》2009年第23期1878-1880,共3页Chinese Journal of Cancer Prevention and Treatment

基　　金：辽宁省科技计划资助项目(2007225005-13)

摘　　要：目的:探讨顺铂(DDP)为基础的联合化疗在非小细胞性肺癌(NSCLC)治疗中对血糖变化的影响。方法:以顺铂为基础的联合化疗患者150例,回顾性分析化疗前后的血糖变化情况及相关临床资料。结果:150例患者中,化疗期间6例(4.00%)确诊为糖尿病(DM),6例(4.00%)出现糖耐量减低(IGT),10例(6.67%)出现空腹血糖受损(IFG),8例(5.33%)一过性血糖升高,继发DM患者化疗前后的平均血糖值分别为(5.08±0.18)和(10.79±2.80)mmol/L,化疗前后空腹血糖水平差异有统计学意义,t=5.200,P=0.003。继发DM多发生在化疗的第3.5个周期,DDP的累积量约280mg/m2。结论:常规剂量顺铂化疗能引起DM、IGT、IFG及一过性血糖升高,化疗期间应密切监测血糖。OBJECTIVE： To explore the change of cisplatin-based chemotherapy on the blood glucose of patients with non-small cell lung cancer （NSCLC）. METHODS： A retrospective study was carried out through the analysis of blood glucose and associated clinical data before and after chemotherapy in 150 patients with NSCLC. RESULTS： Among the 150 cases, 6 pattients with diabetes mellitus （DM, 4.00%） were discovered during the themotherapy, with 6 cases（4.00%）of impaired glucose tolerance（IGT）, 10 eases（6. 67%） of impaired fasting glycaemia（IFG）, and 8 cases （5.33 %） of transient hyperglykemia. The difference of fasting glucose levels of DM patients before and afer chemotherapy had a statistical significance [（5.08±0. 18） mmol/L vs （10. 79±2. 80） retool/L, t=5. 200, P=0. 003]. The median cycles until the diabetes were 3.5 cycle, and the median cisplatin cumulative dose was 280 mg/m^2. CONCLUSIONS： Routine doses of DDP may induce disorders of glucose metabolism including DM, IGT, IFG or transient hyperglykemia. So the glucose change of the patients should be monitored.

关 键 词：顺铂 化疗 血糖 癌 非小细胞肺/药物疗法 

分 类 号：R734.2[医药卫生—肿瘤]